|
1
|
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.
|
N Engl J Med
|
1998
|
4.93
|
|
2
|
Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy.
|
Mol Psychiatry
|
2002
|
2.87
|
|
3
|
Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer.
|
Ann Oncol
|
2014
|
2.29
|
|
4
|
Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state.
|
N Engl J Med
|
1999
|
2.14
|
|
5
|
Sequential sorafenib and sunitinib for renal cell carcinoma.
|
J Urol
|
2009
|
2.12
|
|
6
|
Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie.
|
Ann Oncol
|
2002
|
2.03
|
|
7
|
Taxane-induced glaucoma.
|
Lancet
|
1999
|
2.02
|
|
8
|
Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy.
|
J Clin Oncol
|
2000
|
1.57
|
|
9
|
Adjuvant therapy by BCG of non-Hodgkin's malignant lymphomas in a controlled trial: an update.
|
Br J Haematol
|
1989
|
1.39
|
|
10
|
Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy.
|
Psychoneuroendocrinology
|
2001
|
1.37
|
|
11
|
Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.
|
Eur J Cancer
|
2011
|
1.29
|
|
12
|
Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients.
|
Psychosom Med
|
2001
|
1.20
|
|
13
|
First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma.
|
Ann Oncol
|
2008
|
1.18
|
|
14
|
Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group.
|
J Clin Oncol
|
1999
|
1.14
|
|
15
|
Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma.
|
Ann Oncol
|
2012
|
1.12
|
|
16
|
Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
|
Ann Oncol
|
2009
|
1.03
|
|
17
|
Incidence of large oesophageal varices in patients with cirrhosis: application to prophylaxis of first bleeding.
|
Gut
|
1990
|
1.02
|
|
18
|
Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: case reports.
|
Ann Oncol
|
2009
|
0.97
|
|
19
|
A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy.
|
Blood
|
1998
|
0.97
|
|
20
|
Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape.
|
J Clin Oncol
|
1999
|
0.94
|
|
21
|
Routinely performed multiparametric magnetic resonance imaging helps to differentiate common subtypes of renal tumours.
|
Eur Radiol
|
2014
|
0.90
|
|
22
|
Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers.
|
Eur J Cancer
|
2005
|
0.90
|
|
23
|
Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis.
|
Br J Cancer
|
2012
|
0.87
|
|
24
|
Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer.
|
Ann Oncol
|
2007
|
0.86
|
|
25
|
Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer.
|
Eur J Cancer
|
2003
|
0.85
|
|
26
|
Vinorelbine/5-FU combination in metastatic breast cancer chemotherapy. A retrospective study of 63 cases.
|
Eur J Cancer
|
1996
|
0.85
|
|
27
|
PET scans for decision-making in metastatic renal cell carcinoma: a single-institution evaluation.
|
Oncology
|
2006
|
0.81
|
|
28
|
Combination of gemcitabine and doxorubicin in rapidly progressive metastatic renal cell carcinoma and/or sarcomatoid renal cell carcinoma.
|
Oncology
|
2011
|
0.80
|
|
29
|
Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology.
|
Eur J Cancer
|
2012
|
0.79
|
|
30
|
Multiparametric magnetic resonance imaging for the differentiation of low and high grade clear cell renal carcinoma.
|
Eur Radiol
|
2014
|
0.78
|
|
31
|
Colonic metastasis of a renal carcinoma. A case report.
|
Tumori
|
1992
|
0.78
|
|
32
|
Cardiomyopathy after acute myocardial infarction after therapy with interleukin-2 and tumour infiltrating lymphocytes.
|
Eur J Cancer
|
1992
|
0.78
|
|
33
|
Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy.
|
Neuropsychopharmacology
|
2001
|
0.78
|
|
34
|
[Study of bioavailability parameters of propranolol in cirrhotic patients after oral administration of the delayed-action form].
|
Therapie
|
1987
|
0.78
|
|
35
|
In vitro immunization of patient T cells with autologous bone marrow antigen presenting cells pulsed with tumor lysates.
|
Int J Cancer
|
2000
|
0.77
|
|
36
|
[Systemic chemotherapy in metastatic colorectal adenocarcinomas].
|
Gastroenterol Clin Biol
|
1992
|
0.77
|
|
37
|
[Targeted therapy for locally advanced and/or metastatic bladder cancer].
|
Prog Urol
|
2008
|
0.77
|
|
38
|
VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma.
|
Ann Oncol
|
2009
|
0.76
|
|
39
|
[Does surgery promote the development of metastasis in melanoma?].
|
Ann Chir Plast Esthet
|
2000
|
0.76
|
|
40
|
[Hand-foot syndrome and sorafenib].
|
Bull Cancer
|
2009
|
0.76
|
|
41
|
Ten-year experience of percutaneous image-guided radiofrequency ablation of malignant renal tumours in high-risk patients.
|
Eur Radiol
|
2013
|
0.76
|
|
42
|
Pharmacodynamic and pharmacokinetic study of propranolol in patients with cirrhosis and portal hypertension.
|
Br J Clin Pharmacol
|
1989
|
0.76
|
|
43
|
Gastric lipase in alcoholic pancreatitis. Comparison of secretive profiles following pentagastrin stimulation in normal adults and patients with pancreatic insufficiency.
|
Gastroenterology
|
1990
|
0.75
|
|
44
|
Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies Group.
|
Melanoma Res
|
1999
|
0.75
|
|
45
|
Phase II study of interferon-alpha and all-trans retinoic acid in metastatic renal cell carcinoma.
|
J Immunother
|
1998
|
0.75
|
|
46
|
In vitro production of human antigen presenting cells issued from bone marrow of patients with cancer.
|
Hematol Cell Ther
|
1997
|
0.75
|
|
47
|
Cancer chemotherapy in the elderly: a series of 51 patients aged greater than 70 years.
|
Cancer Chemother Pharmacol
|
1991
|
0.75
|
|
48
|
[Not value to the systematic study of different tumor markers for disclosing bone metastasis].
|
Presse Med
|
1989
|
0.75
|
|
49
|
[Radiofrequency ablation in the treatment of liver and lung tumors].
|
Bull Cancer
|
2009
|
0.75
|
|
50
|
[Treatment of cancer of the kidney with interleukin 2 in adults, the Lyon experience].
|
J Chir (Paris)
|
1993
|
0.75
|
|
51
|
Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction.
|
Invest New Drugs
|
2012
|
0.75
|
|
52
|
Phase I dose-escalation study of oral vinflunine administered once daily for 6 weeks every 8 weeks in patients with advanced/metastatic solid tumours.
|
Cancer Chemother Pharmacol
|
2013
|
0.75
|
|
53
|
[Neoadjuvant chemotherapy and combined conservative treatment of soft tissue sarcoma in the adult].
|
Bull Cancer
|
1992
|
0.75
|
|
54
|
[Renal cell carcinoma: the end of a tunnel?].
|
Pathol Biol (Paris)
|
2006
|
0.75
|
|
55
|
[Perception of cancer by general practitioners. Development over 15 years].
|
Bull Cancer
|
1993
|
0.75
|
|
56
|
[The advantages of antiangiogenics in neoadjuvant and adjuvant locally advanced and metastatic kidney cancer: two case studies].
|
Prog Urol
|
2008
|
0.75
|
|
57
|
High-dose interleukin-2 two days a week for metastatic renal cell carcinoma: a FNCLCC multicenter study.
|
J Immunother Emphasis Tumor Immunol
|
1994
|
0.75
|
|
58
|
[Gallbladder collapse in drug-induced hepatitis].
|
Presse Med
|
1986
|
0.75
|
|
59
|
[Role of adjuvant chemotherapy in the treatment of soft tissue sarcoma].
|
Bull Cancer
|
1997
|
0.75
|
|
60
|
Evaluation of medical students' hospital training: interest of students' essays.
|
J Cancer Educ
|
1992
|
0.75
|
|
61
|
[What is the clinical practice of partial nephrectomy in France?].
|
Prog Urol
|
2008
|
0.75
|
|
62
|
[Management of muscle invasive bladder in elderly].
|
Prog Urol
|
2010
|
0.75
|
|
63
|
[Bladder cancer and new drugs].
|
Bull Cancer
|
2010
|
0.75
|
|
64
|
Investigation of total and conjugated bilirubin determination during the neonatal period.
|
Eur J Clin Chem Clin Biochem
|
1993
|
0.75
|
|
65
|
[Relay chemotherapy using continuous perfusion of cisplatin and fluoro-uracil in advanced cancer of the breast. Analysis of a series of 50 cases].
|
Rev Fr Gynecol Obstet
|
1990
|
0.75
|
|
66
|
[Is the incidence of painless chronic pancreatitis underestimated?].
|
Gastroenterol Clin Biol
|
1989
|
0.75
|
|
67
|
[Symptomatic treatment of pain in cervico-facial cancers].
|
Rev Laryngol Otol Rhinol (Bord)
|
1992
|
0.75
|